Pfizer Positions For First-In-Class Nasal Corticosteroid Switch
This article was originally published in The Tan Sheet
Executive Summary
Rhinocort Aqua could be a first-in-class U.S. switch for the nasal corticosteroids, often cited as a potential class for switches. Pfizer gains right of first refusal for the product’s OTC rights from AstraZeneca.
You may also be interested in...
Sanofi’s Nasacort AQ Rx-To-OTC Switch Under FDA Review
FDA’s Nonprescription Drugs Advisory Committee will meet July 31 to discuss Sanofi’s application to switch the intranasal corticosteroid Nasacort AQ to OTC sale, to be indicated for relief of hay fever symptoms in adults and children.
Sanofi’s Nasacort AQ Rx-To-OTC Switch Under FDA Review
FDA’s Nonprescription Drugs Advisory Committee will meet July 31 to discuss Sanofi’s application to switch the intranasal corticosteroid Nasacort AQ to OTC sale, to be indicated for relief of hay fever symptoms in adults and children.
Promise Of A New Day For Rx-To-OTC Switch Ruled 2012 In “The Tan Sheet”
The most popular stories in “The Tan Sheet” during 2012 dealt with FDA’s nonprescription safe use regulatory extension initiative, as well as planned switches by Pfizer and Merck. In dietary supplements, coverage of firms struggling with GMPs and congressional threats to DSHEA drew the most interest.